Klonopin, Rivotril, and Syn-clonazepam (clonazepam) are included in the benzodiazepine class of medicines from a group used as central nervous system depressants. Its mechanism of action is not very well understood, but it is believed that clonazepam enhances the activity of the central nervous system’s major inhibitory neurotransmitter, slowing it down. Clonazepam is mainly used to treat seizures and panic attacks, but it is sometimes used to treat tremor and to manage pain or spasticity in diseases such as multiple sclerosis (MS) when other medicines fail.

Some side effects of clonazepam include drowsiness, problems with walking and coordination, dizziness, depression, fatigue, and problems with memory.

Clonazepam has a black box warning that appears on the prescription drug label to call attention to serious or life-threatening risks. Clonazepam and other drugs in the same class of medicines can result in profound sedation, breathing difficulties, depression, coma, and death.

Generic medicines are available.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

#ECTRIMS2018 — Data from 2 EU Trials Shows Effectiveness of Cannabidiol Spray in Treating Spasticity

Data from two European trials — a real-life study in Italy, and a long-term Czech trial looking at impact on cognition — supported the efficacy of a widely approved cannabinoid spray in treating moderate to severe spasticity (muscular stiffness or involuntary spasms) in multiple sclerosis (MS) patients who failed to benefit from other spasticity treatments. […]

Spasticity Scales May Not Be Sufficiently Informative of Sativex Benefits in MS Patients, Small Study Suggests

Spasticity scales may be insufficient to reflect the actual benefits of Sativex (nabiximols) treatment on spasticity symptoms in people with multiple sclerosis (MS), according to a small case series study. The results support the need to conduct a more extensive and functional examination to clarify treatment responses and help optimize treatment decisions. The study, “Variability […]

Using Medical Marijuana for MS Symptoms May Affect Your Employment

Ohio, my home state, is wrestling with the nuances of medical marijuana laws that become effective on Sept. 8, 2018. My husband’s work email had an important notice from the Bureau of Worker’s Compensation (BWC) about this pending change, and as I read it, I thought that nothing really changed. Although medical marijuana legalization has […]

MedChew RX Shows Stability and Potential for Effectiveness in Early Tests, Company Reports

AXIM Biotech announced that tests done on its cannabinoid-based chewing gum — MedChew Rx — showed both product stability and effective release of medicinal molecules, with a high percentage of its pharmaceutical ingredients available. These test results may be of importance, as the company is planning to bring MedChew Rx into clinical trials as a treatment for pain and spasticity in multiple sclerosis […]

Multiple Sclerosis Patients Identify Symptoms that Worsen Quality of Life

Loss of health-related quality of life is caused mostly by balance problems, muscle stiffness, and depression in people with relapsing-remitting multiple sclerosis (RRMS), and for those with progressive MS, the causes are muscle rigidity, paralysis, weakness, and pain, according to a study based on patient-reported outcomes. The study, “The disease burden of Multiple Sclerosis from the individual […]

Axim Biotech Given Patent for Method of Making Medical Cannabis Compound

Axim Biotech announced that its way of extracting and purifying THC (delta-9-tetrahydrocannabinol) — an active compound in medical cannabis — has been approved to receive a patent. The notice of allowance for patient No. 15/146668 came in letter from the United States Patent and Trademark Office (USPTO), Axim said in a press release. Axim specializes in the research […]

MMJ Bioscience Files Request with FDA to Open Phase 2 Study of Medical Cannabis in Progressive MS

MMJ Bioscience, which specializes in medical cannabis products, has filed a request with the U.S. Food and Drug Administration (FDA) to open Phase 2 clinical trials evaluating the company’s THC/CBD pharmaceutical compounds as possible treatments for symptoms of multiple sclerosis (MS). THC refers to the tetrahydrocannabinol compound, part of the cannabis plant. CBD stands for cannabidiol, […]

#CMSC2018 – Pharmacist Discusses Advances, Challenges in Cannabinoids Research to Treat MS

Several studies have demonstrated the therapeutic potential of cannabis and its derivate products to manage the symptoms of multiple sclerosis (MS) and other neurodegenerative diseases. But there is still much to be done to enhance their use and accessibility to patients who may benefit from these therapies, according to a recent presentation by Matthew Makelky, […]

PathMaker Neurosystems, Developing MyoRegulator for Spasticity, Named Startup of Year at French-American Business Gala

PathMaker Neurosystems, which specializes in non-invasive devices to treat chronic neuromotor disorders, won the 2018 French-American Business (FAB) Award in the startup/small company category. PathMaker, based in Boston, is developed and testing MyoRegulator, a potential treatment for muscle spasticity in people with multiple sclerosis (MS), cerebral palsy and other chronic conditions. The honor was among several given to companies at […]